CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D019851: Thrombophilia NIH

(Synonyms: Thrombophilia)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug1613 Low Molecular Weight Heparin Wiki 0.58
drug2218 Predictors of health care provide Wiki 0.58
drug2217 Predictors adverse evolution Wiki 0.58
drug1058 Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter Wiki 0.58
drug3209 blood sampling Wiki 0.26

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D018352 Coronavirus Infections NIH 0.02

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0100724 Hypercoagulability HPO 1.00

There are 3 clinical trials

Clinical Trials


1 Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19

Coronavirus COVID-19 is an emerging virus also called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Eighty percent of patients are poor or asymptomatic. However, there are major respiratory complications for some patients, requiring intensive care hospitalization and possibly leading to death in 5% of cases. One of the hypotheses put forward is that much of the pathophysiology is due to endothelial dysfunction associated with disseminated intravascular coagulation. The covid-19 pathology could induce coagulation impairment as observed during sepsis. An increase in D-dimer levels during covid-19 disease is itself associated with excess mortality. While D-dimers are highly sensitive, they are not specific for clotting activity. They may be increased in many other circumstances, particularly in inflammation. On the other hand, the infection stimulates the release of extracellular vesicles. These vesicles, of multiple cellular origin, are an actor of vascular homeostasis, and participate in the state of hyperactivation of coagulation. They have a major role in the prothrombotic state and the development of coagulopathy associated with sepsis. The aim of our monocentric prospective study would be to study early and more specific markers of hypercoagulability and markers of routine endothelial dysfunction, as soon as the patient is hospitalized, in order to predict the risk of hospitalization in intensive care.

NCT04367662 COVID-19 Procedure: blood sampling
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Thrombophilia
HPO:Hypercoagulability

Primary Outcomes

Measure: Clinical worsening (yes/no) of the patient during hospitalization

Time: in the 15 days from admission

Description: Biological analysis using initial blood sampling

Measure: D-DIMERS plasma levels in blood

Time: 1 hour after admission

Description: Biological analysis using initial blood sampling

Measure: Fibrin monomers plasma levels in blood

Time: 1 hour after admission

Description: Biological analysis using initial blood sampling

Measure: Antithrombin plasma levels in blood

Time: 1 hour after admission

Description: Biological analysis using initial blood sampling

Measure: Prothrombin Fragment 1 plasma levels in blood

Time: 1 hour after admission

Description: Biological analysis using initial blood sampling

Measure: Prothrombin Fragment 2 plasma levels in blood

Time: 1 hour after admission

Description: Biological analysis using initial blood sampling

Measure: Thrombin generation test plasma levels in blood

Time: 1 hour after admission

Description: Biological analysis using initial blood sampling

Measure: Microvesicles of platelet plasma levels in blood

Time: 1 hour after admission

Description: Biological analysis using initial blood sampling

Measure: Cross-linked platelets plasma levels in blood

Time: 1 hour after admission

Description: Biological analysis using initial blood sampling

Measure: Willebrand Factor plasma levels in blood

Time: 1 hour after admission

Description: Biological analysis using initial blood sampling

Measure: Factor VIII plasma levels in blood

Time: 1 hour after admission

2 Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto

The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.

NCT04393805 COVID-19 Hypercoagulability Drug: Low Molecular Weight Heparin
MeSH:Thrombophilia
HPO:Hypercoagulability

Primary Outcomes

Description: Collect and evaluate in real-life the safety data of the anti-coagulant treatments used by estimating the incidence of bleeding complications during hospitalization.

Measure: Bleeding

Time: 28 days

Description: Collect and evaluate in real-life the efficacy data of the anti-coagulant treatments used by estimating the incidence of deep vein thrombosis and/or pulmonary embolism during hospitalization.

Measure: Thrombosis

Time: 28 days

Description: Collect and evaluate in real-life the data by estimating incidence of intra-hospital death.

Measure: Mortality

Time: 28 days

Secondary Outcomes

Description: clinical worsening with transfer to the intensive/sub-intensive ward

Measure: Worsening

Time: 28 days

Description: length of stay

Measure: LOS

Time: 60 days

3 Clinical Efficacy and Safety of Extracorporeal Blood Purification to Control Hyperinflammation and Hypercoagulability in COVID-19 Patients

Several studies have suggested a potential clinical benefit of controlling hyper inflammation triggered by SARS-CoV-2/COVID-19. Blood purification, the removal of excessive proinflammatory mediators may control disease progression and support clinical recovery. For this purpose, COVID-19 patients might benefit from treatment with AN69ST hemofilter based extracorporeal blood purification.

NCT04478539 Covid19 Device: Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter
MeSH:Thrombophilia
HPO:Hypercoagulability

Primary Outcomes

Description: Systemic levels of IL-6, IL-8 and TNF-α are evaluated to assess the effect of blood purification. Measurement points: at admission, "before and after a blood purification cycle" and before discharge

Measure: Changes in cytokine levels of Interleukin (IL) 6, IL-8 and Tumor Necrosis Factor-α (pg/mL)

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

Description: Systemic levels of proinflammatory mediators are measured as a marker for disease severity. Measurement points: at admission, "before and after a blood purification cycle" and before discharge.

Measure: Changes in inflammatory markers; C-Reactive Protein (CRP) (mg/L)

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

Description: Systemic levels of thrombocytes are measured as a marker for disease severity. Measurement points: at admission, "before and after a blood purification cycle" and before discharge.

Measure: Changes in thrombocyte counts (10^3 counts/microL)

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

Description: Coagulation markers will be followed to assess the effect of systemic heparinisation, Measurement points, at admission, "before and after a blood purification cycle" and before discharge

Measure: Changes in the coagulation marker Fibrinogen (g/L)

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

Description: Duration of intensive care will be determined in relation to the number of blood purification cycles Patients will be followed for the duration of ICU stay.

Measure: ICU length of stay after admission (days)

Time: An expected average of 4 - 14 hospitalisation days or until hospital discharge (whichever comes first)

Secondary Outcomes

Description: Systemic levels of proinflammatory mediators are measured as a marker for disease severity. Measurement points: at admission, "before and after a blood purification cycle" and before discharge.

Measure: Changes in Neutrophil-to-Lymphocyte Ratio

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

Description: Coagulation markers will be followed to assess the effect of systemic heparinisation, Measurement points, at admission, "before and after a blood purification cycle" and before discharge

Measure: Changes in the coagulation marker D-Dimers (ng/mL)

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

Description: Coagulation markers will be followed to assess the effect of systemic heparinisation, Measurement points, at admission, "before and after a blood purification cycle" and before discharge

Measure: Changes in the Activation Clotting Time (seconds).

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)


HPO Nodes